New All-Oral CLL Regimen Offers Fixed-Duration Treatment Option

The approval by the U.S. Food and Drug Administration (FDA) of Venclexta (venetoclax) in combination with Calquence (acalabrutinib) marks a notable advancement in the frontline treatment of chronic lymphocytic leukemia (CLL), according to a press release from Genentech, a member of the Roche Group.

Based on findings from the AMPLIFY trial, this regimen introduces the first fully oral, fixed-duration treatment option in this setting, reflecting a broader shift toward targeted, chemotherapy-free approaches. For patients, this approval introduces a regimen designed to balance efficacy with convenience and quality of life.

To better understand the clinical significance of this approval and what it means for patients, CURE sat down with Dr. John Burke, a hematologist and medical oncologist at Rocky Mountain Cancer Centers.

CURE: Can you discuss the significance of the FDA approval of Venclexta plus Calquence for previously untreated CLL and what it means for patients?

Burke: The FDA approval of Venclexta in combination with Calquence in frontline CLL is an important advancement because this combination is the first and only fully oral, fixed‑duration regimen in the field. It represents a meaningful advancement for those seeking strong disease control and personalization of their treatment journey.

Additionally, this new combination adds to the treatment options available for CLL patients and healthcare providers, empowering them to choose the combination that best meets the patient's individual treatment goals and preferences.

How does an all-oral, fixed-duration regimen impact patient quality of life compared with traditional treatment options?

This regimen is completed over a defined treatment period, which eliminates the need for infusion appointments. This may reduce time spent in the clinic and allow patients to integrate treatment more seamlessly into their daily lives.

For many individuals, knowing there is a defined endpoint to therapy can provide both physical and emotional benefits compared with continuous treatment strategies.

Are there specific patient populations who may particularly benefit from this regimen?

The AMPLIFY study enrolled previously untreated adults with CLL, including patients across a broad range of risk profiles. Its fully oral, fixed-duration design may be especially appealing to patients who prefer the potential for time off therapy.

What challenges or considerations should clinicians keep in mind when initiating patients on this combination therapy?

In the AMPLIFY trial, the safety profile of Venclexta and Calquence was consistent with what is already known for each medicine individually. As with any CLL therapy, appropriate patient selection, monitoring and education are essential. Clinicians should follow the prescribing information for both agents.

How do you see this approval influencing the broader landscape of first-line CLL treatment moving forward?

This approval further reinforces the shift toward targeted, chemotherapy-free therapy in the frontline CLL setting.

Going forward, treatment decisions will increasingly center on aligning the therapy’s duration, administration, and side-effect profile with each patient’s individual goals and lifestyle.

Are there any practical tips or advice you would offer patients considering this treatment regarding monitoring, adherence, or lifestyle consideration?

Education and communication are key. Patients should have a clear understanding of the dosing schedule and the importance of keeping scheduled lab appointments for monitoring.

Most importantly, patients should feel empowered to ask questions and actively participate in shared decision making. With today’s advances in CLL treatment, we are increasingly able to work with patients to determine the most appropriate regimen based on the approved label, supporting clinical evidence and the individual patient’s needs.

Transcript edited for clarity and conciseness

References

1. “FDA Approves Calquence Plus Venclexta for CLL and SLL,” by Spencer Feldman. CURE; Feb. 20, 2026. https://www.curetoday.com/view/fda-approves-calquence-plus-venclexta-for-cll-and-sll.
2. “FDA Approves Genentech’s Venclexta® Plus Acalabrutinib Combination Regimen for Previously Untreated Chronic Lymphocytic Leukemia,” by Genentech. News Release; Feb. 19, 2026.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.